AbOliGo

AbOliGo is a biotechnology company headquartered in Cambridge, UK, that specializes in the production of high-performance antibody-oligonucleotide conjugates (AOCs). The company has developed a proprietary conjugation platform designed to deliver fast, reproducible, and customizable AOCs, addressing a critical bottleneck in the availability of research-grade reagents. Their approach includes miniaturized process development that enables conjugation with minimal antibody input, as well as semi-automated manufacturing to enhance throughput and precision. By streamlining the transition from antibody to multiomic insight, AbOliGo provides research tools essential for advanced applications such as proteomics, spatial biology, and single-cell analysis.

This technology is vital for scientists seeking to expand multiomic capabilities, as only a small fraction of commercially available antibodies are currently offered as AOCs. By providing assay-ready conjugates with quantitative quality control, AbOliGo helps researchers overcome the significant time and technical hurdles typically associated with in-house or external conjugation workflows. The company's services and tools are aimed at accelerating scientific discovery by making multiomic workflows more accessible, flexible, and consistent for both academic and translational research laboratories. Supported by successful seed funding and a board of experienced life sciences industry leaders, AbOliGo is scaling its operations to meet the increasing demand for these critical reagents in the global research market.